FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386904851> ?p ?o ?g. }

• W4386904851 endingPage "102225" @default.
• W4386904851 startingPage "102225" @default.
• W4386904851 abstract "Molnupiravir and nirmatrelvir-ritonavir have emerged as promising options for COVID-19 treatment, but direct comparisons of their effectiveness have been limited. This study aimed to compare the effectiveness of these two oral antiviral drugs in non-hospitalised and hospitalised patients with COVID-19.In this target trial emulation study, we used data from a territory-wide electronic health records database on eligible patients aged ≥18 years infected with COVID-19 who were prescribed either molnupiravir or nirmatrelvir-ritonavir within five days of infection between 16 March 2022 and 31 December 2022 in the non-hospitalised and hospitalised settings in Hong Kong. A sequence trial approach and 1:1 propensity score matching was applied based on age, sex, number of COVID-19 vaccine doses received, Charlson comorbidity index, comorbidities, and drug use within past 90 days. Cox regression adjusted with patients' characteristics was used to compare the risk of effectiveness outcomes (all-cause mortality, intensive care unit (ICU) admission or ventilatory support and hospitalisation) between groups. Subgroup analyses included age (<70; ≥70 years); sex, Charlson comorbidity index (<4; ≥4), and number of COVID-19 vaccine doses received (0-1; ≥2 doses).A total of 63,522 non-hospitalised (nirmatrelvir-ritonavir: 31,761; molnupiravir: 31,761) and 11,784 hospitalised (nirmatrelvir-ritonavir: 5892; molnupiravir: 5892) patients were included. In non-hospitalised setting, 336 events of all-cause mortality (nirmatrelvir-ritonavir: 71, 0.22%; molnupiravir: 265, 0.83%), 162 events of ICU admission or ventilatory support (nirmatrelvir-ritonavir: 71, 0.22%; molnupiravir: 91, 0.29%), and 4890 events of hospitalisation (nirmatrelvir-ritonavir: 1853, 5.83%; molnupiravir: 3037, 9.56%) were observed. Lower risks of all-cause mortality (absolute risk reduction (ARR) at 28 days: 0.61%, 95% CI: 0.50-0.72; HR: 0.43, 95% CI: 0.33-0.56) and hospital admission (ARR at 28 days: 3.73%, 95% CI: 3.31-4.14; HR: 0.72, 95% CI: 0.67-0.76) were observed in nirmatrelvir-ritonavir users compared to molnupiravir users. In hospitalised setting, 509 events of all-cause mortality (nirmatrelvir-ritonavir: 176, 2.99%; molnupiravir: 333, 5.65%), and 50 events of ICU admission or ventilatory support (nirmatrelvir-ritonavir: 26, 0.44%; molnupiravir: 24, 0.41%) were observed. Risk of all-cause mortality was lower for nirmatrelvir-ritonavir users than for molnupiravir users (ARR at 28 days: 2.66%, 95% CI: 1.93-3.40; HR: 0.59, 95% CI: 0.49-0.71). In both settings, there was no difference in the risk of intensive care unit admission or ventilatory support between groups. The findings were consistent across all subgroup's analyses.Our analyses suggest that nirmatrelvir-ritonavir was more effective than molnupiravir in reducing the risk of all-cause mortality in both non-hospitalised and hospitalised patients. When neither drug is contraindicated, nirmatrelvir-ritonavir may be considered the more effective option.HMRF Research on COVID-19, The Hong Kong Special Administrative Region (HKSAR) Government; Collaborative Research Fund, University Grants Committee, the HKSAR Government; and Research Grant from the Food and Health Bureau, the HKSAR Government; the Laboratory of Data Discovery for Health (D24H) funded by the AIR@InnoHK administered by Innovation and Technology Commission." @default.
• W4386904851 created "2023-09-21" @default.
• W4386904851 creator A5004488408 @default.
• W4386904851 creator A5015797411 @default.
• W4386904851 creator A5025936391 @default.
• W4386904851 creator A5033684035 @default.
• W4386904851 creator A5035152212 @default.
• W4386904851 creator A5041610413 @default.
• W4386904851 creator A5043051253 @default.
• W4386904851 creator A5061769000 @default.
• W4386904851 creator A5063190766 @default.
• W4386904851 creator A5066384550 @default.
• W4386904851 creator A5090788920 @default.
• W4386904851 date "2023-10-01" @default.
• W4386904851 modified "2023-09-29" @default.
• W4386904851 title "Effectiveness of molnupiravir vs nirmatrelvir-ritonavir in non-hospitalised and hospitalised patients with COVID-19: a target trial emulation study" @default.
• W4386904851 cites W2062359643 @default.
• W4386904851 cites W2112662877 @default.
• W4386904851 cites W2298338128 @default.
• W4386904851 cites W2735301415 @default.
• W4386904851 cites W2955326815 @default.
• W4386904851 cites W3131688063 @default.
• W4386904851 cites W3193761537 @default.
• W4386904851 cites W3202672160 @default.
• W4386904851 cites W3205044984 @default.
• W4386904851 cites W3215925352 @default.
• W4386904851 cites W4200051875 @default.
• W4386904851 cites W4200200825 @default.
• W4386904851 cites W4205962841 @default.
• W4386904851 cites W4207009506 @default.
• W4386904851 cites W4210860013 @default.
• W4386904851 cites W4210887330 @default.
• W4386904851 cites W4214649932 @default.
• W4386904851 cites W4224038493 @default.
• W4386904851 cites W4226236384 @default.
• W4386904851 cites W4226318522 @default.
• W4386904851 cites W4229038932 @default.
• W4386904851 cites W4285719527 @default.
• W4386904851 cites W4293217726 @default.
• W4386904851 cites W4293280590 @default.
• W4386904851 cites W4312134853 @default.
• W4386904851 cites W4319870639 @default.
• W4386904851 cites W4323355832 @default.
• W4386904851 cites W4324026749 @default.
• W4386904851 cites W4324332959 @default.
• W4386904851 cites W4379380907 @default.
• W4386904851 doi "https://doi.org/10.1016/j.eclinm.2023.102225" @default.
• W4386904851 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37753272" @default.
• W4386904851 hasPublicationYear "2023" @default.
• W4386904851 type Work @default.
• W4386904851 citedByCount "0" @default.
• W4386904851 crossrefType "journal-article" @default.
• W4386904851 hasAuthorship W4386904851A5004488408 @default.
• W4386904851 hasAuthorship W4386904851A5015797411 @default.
• W4386904851 hasAuthorship W4386904851A5025936391 @default.
• W4386904851 hasAuthorship W4386904851A5033684035 @default.
• W4386904851 hasAuthorship W4386904851A5035152212 @default.
• W4386904851 hasAuthorship W4386904851A5041610413 @default.
• W4386904851 hasAuthorship W4386904851A5043051253 @default.
• W4386904851 hasAuthorship W4386904851A5061769000 @default.
• W4386904851 hasAuthorship W4386904851A5063190766 @default.
• W4386904851 hasAuthorship W4386904851A5066384550 @default.
• W4386904851 hasAuthorship W4386904851A5090788920 @default.
• W4386904851 hasConcept C126322002 @default.
• W4386904851 hasConcept C142462285 @default.
• W4386904851 hasConcept C159047783 @default.
• W4386904851 hasConcept C17923572 @default.
• W4386904851 hasConcept C187212893 @default.
• W4386904851 hasConcept C194828623 @default.
• W4386904851 hasConcept C2776376669 @default.
• W4386904851 hasConcept C2779134260 @default.
• W4386904851 hasConcept C2779159551 @default.
• W4386904851 hasConcept C2779298103 @default.
• W4386904851 hasConcept C2993143319 @default.
• W4386904851 hasConcept C3008058167 @default.
• W4386904851 hasConcept C3013748606 @default.
• W4386904851 hasConcept C524204448 @default.
• W4386904851 hasConcept C71924100 @default.
• W4386904851 hasConceptScore W4386904851C126322002 @default.
• W4386904851 hasConceptScore W4386904851C142462285 @default.
• W4386904851 hasConceptScore W4386904851C159047783 @default.
• W4386904851 hasConceptScore W4386904851C17923572 @default.
• W4386904851 hasConceptScore W4386904851C187212893 @default.
• W4386904851 hasConceptScore W4386904851C194828623 @default.
• W4386904851 hasConceptScore W4386904851C2776376669 @default.
• W4386904851 hasConceptScore W4386904851C2779134260 @default.
• W4386904851 hasConceptScore W4386904851C2779159551 @default.
• W4386904851 hasConceptScore W4386904851C2779298103 @default.
• W4386904851 hasConceptScore W4386904851C2993143319 @default.
• W4386904851 hasConceptScore W4386904851C3008058167 @default.
• W4386904851 hasConceptScore W4386904851C3013748606 @default.
• W4386904851 hasConceptScore W4386904851C524204448 @default.
• W4386904851 hasConceptScore W4386904851C71924100 @default.
• W4386904851 hasLocation W43869048511 @default.
• W4386904851 hasLocation W43869048512 @default.
• W4386904851 hasOpenAccess W4386904851 @default.
• W4386904851 hasPrimaryLocation W43869048511 @default.
• W4386904851 hasRelatedWork W2011443172 @default.

• next